Shrinal Inamdar

Liminal BioSciences Receives FDA Approval for its US-based Plasma Collection Center

Prometic Plasma Resources (USA) Inc., has received U.S. Food and Drug Administration (“FDA”) approval for its plasma collection center located in Amherst, NY.

Liminal BioSciences Announces First Subject Dosed in Phase 1 Multiple Ascending Dose Clinical Trial of Fezagepras

LMNL today announced that the first subject has been dosed in the Company’s fezagepras Phase 1 multiple ascending dose clinical trial in healthy volunteers.

Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at The ASH Conference

LMNL announced the presentation of two scientific posters highlighting potential activity of intravenous Ryplazim® (plasminogen) on infertility and acute airway obstruction in patients with C-PLGD.

Liminal Biosciences to Present at The Stifel Virtual Healthcare Conference

LMNL is scheduled to present a company overview at The Stifel 2020 Virtual Healthcare Conference on Monday 16th November at 2:40-3:10 PM (EDT)

Liminal BioSciences Reports Third Quarter Financial Results

LMNL today reported its unaudited financial results for the third quarter ended September 30, 2020.

Liminal Biosciences to Reschedule Reporting of Q3 2020 Results and Conference Call

LMNL will now report its financial results for the third quarter ended September 30th 2020 on Thursday November 12, 2020 after market close.

Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim® (plasminogen) BLA

PDUFA date extended by FDA from March 5, 2021 to June 5, 2021 Earnings call moved forward to Wednesday November 11th

Liminal Biosciences To Report Q3 2020 Results And Hold Conference Call

LMNL will report its financial results for the third quarter ended September 30th 2020 on Thursday November 12, 2020 after market close.

Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition

LMNL announced the acceptance of two abstracts related to the Company’s clinical development activities of Ryplazim®

Liminal Biosciences to Present at The H.C. Wainwright 22nd Annual Global Investment Conference

LMNL announced that Kenneth Galbraith, Chief Executive Officer at Liminal BioSciences is scheduled to present a company overview at The H.C. Wainwright 22nd Annual Global Investment Conference

Liminal BioSciences Announces Resubmission of Biologics License Application to U.S. Food and Drug Administration for Ryplazim® (plasminogen)

Liminal, through its U.S. subsidiary Prometic Biotherapeutics Inc., has filed a resubmission of the Biologics License Application (BLA) for Ryplazim® (plasminogen) (Ryplazim®) with the U.S. FDA

Liminal BioSciences reports financial results for Q2-2020

Liminal Biosciences to Present at Canaccord 40th Annual Growth Conference

Liminal BioSciences is scheduled to present a company overview at Canaccord 40th Annual Growth Conference on Thursday 13th August 2:00-2:25 PM (EDT)

Liminal Biosciences to Voluntarily Delist from the Toronto Stock Exchange

LMNL announces that it has applied for a voluntarily delisting of its common shares (“Common Shares”) from the Toronto Stock Exchange (“TSX”) in Canada.

Liminal BioSciences Broadens R&D Pipeline With Novel Preclinical Program For Eosinophilic-Driven Diseases

Liminal BioSciences Joins CoVIg Plasma Alliance to Contribute to Development of Potential New COVID-19 Therapy

LMNL announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences Inc., has joined the CoVIg-19 Plasma Alliance.

Liminal BioSciences Commences Collection of Convalescent Plasma from COVID-19 Recovered Donors

LMNL today announced that Prometic Plasma Resources, a subsidiary of Liminal BioSciences, has commenced the collection of convalescent plasma from donors who have recovered from COVID-19.

Liminal BioSciences Provides Guidance on Certain Expected Key Milestones For 2020

LMNL today provided a guidance update on the timing of certain expected key milestones for 2020